New Drug Approved to Prevent Ulcers from Common Pain Meds

Millions of people who take common pain medications for arthritis and chronic pain just got a new way to protect their stomachs from harmful side effects.

South Korea's Ministry of Food and Drug Safety approved K-CAB, a drug already used to treat acid reflux, for a new use: preventing ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs). These everyday pain relievers include ibuprofen, naproxen, and celecoxib.

The approval matters because long-term use of NSAIDs can cause serious stomach problems, including painful ulcers in the stomach and small intestine. As populations age and more people live with chronic pain, the number of patients needing both pain relief and stomach protection continues to grow.

K-CAB works differently than older stomach medications. In a clinical trial lasting 24 weeks, researchers compared K-CAB with lansoprazole, a traditional stomach protector. The study followed patients using 11 different types of NSAIDs for conditions like arthritis and chronic pain.

The results showed K-CAB worked just as well as the older medication at preventing ulcers. But it offered an extra benefit: significantly more patients taking K-CAB remained free from heartburn at 12 weeks compared to those taking the comparison drug.

The medication's safety held up even after six months of continuous use. This matters for patients who need long-term pain management and can't risk adding new health problems from their medications.

The Ripple Effect

K-CAB now has six approved uses, the broadest range of any drug in its class. Since its launch in 2019, it has become the most prescribed anti-ulcer medication in South Korea's outpatient market, with over $681 million in cumulative sales.

The drug's reach extends beyond Korea. It's now licensed in 55 countries and actively sold in 20, including China and several Latin American nations. In January, the company's U.S. partner submitted an application to the Food and Drug Administration, potentially bringing the medication to America's large market of chronic pain patients.

For patients juggling multiple medications to manage pain and its side effects, having one proven option that addresses both concerns could simplify treatment and improve quality of life. The clinical evidence supporting this new use gives doctors another tool to help patients stay active and pain-free without sacrificing digestive health.

This approval represents years of research translating into real-world help for people managing the difficult balance between pain relief and protecting their overall health.

##